DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



AL-15469A for the Treatment of Bacterial Conjunctivitis

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bacterial Conjunctivitis

Intervention: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5% (Drug); Moxifloxacin hydrochloride ophthalmic solution 0.5% as base (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Alcon Research

Summary

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Clinical Details

Official title: An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Clinical cure and microbiological success

Secondary outcome: Individual signs and symptoms of bacterial conjunctivitis at each visit

Eligibility

Minimum age: 1 Month. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- signs and symptoms of bacterial conjunctivitis

- Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

- under 1 mo. age

- Other protocol-defined exclusion criteria may apply

Locations and Contacts

Contact Alcon for Trial Locations, Fort Worth, Texas 76134, United States
Additional Information

Starting date: May 2006
Last updated: March 1, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017